Home
Christian A. Vedeler's picture

Christian A. Vedeler

Professor, in Neurology
  • E-mailChristian.Vedeler@uib.no
  • Phone+47 55 97 51 06+47 918 37 971
  • Visitor Address
    Dept.of Neurology, Old main building, Haukeland University Hospital
  • Postal Address
    Postboks 7804
    5020 Bergen
Academic article
  • 2019. The kynurenine pathway and cognitive performance in community-dwelling older adults. The Hordaland Health Study. Brain, behavior, and immunity. 155-162.
  • 2019. Optimization of receptor occupancy assays in mass cytometry: Standardization across channels with QSC beads. Cytometry Part A. 314-222.
  • 2019. Mitochondrial complex IV is lost in neurons in the cuprizone mouse model. Mitochondrion (Amsterdam. Print). 58-62.
  • 2019. Candidate markers for stratification and classification in rheumatoid arthritis. Frontiers in Immunology. 1-8.
  • 2019. Can serum GAD65 antibody levels predict neurological disease or cancer? Journal of Neuroimmunology. 1-3.
  • 2019. CDR2L Is the Major Yo Antibody Target in Paraneoplastic Cerebellar Degeneration. Annals of Neurology. 316-321.
  • 2018. Reduced glucose transporter-1 in brain derived circulating endothelial cells in mild Alzheimer's disease patients. Brain Research. 304-309.
  • 2018. Paraneoplastic cerebellar degeneration: Yo antibody alters mitochondrial calcium buffering capacity. Neuropathology and Applied Neurobiology. 141-156.
  • 2018. G1m1 predominance of intrathecal virus-specific antibodies in multiple sclerosis. Annals of clinical and translational neurology. 1303-1309.
  • 2018. Expression of the onconeural protein CDR1 in cerebellum and ovarian cancer. OncoTarget. 23975-23986.
  • 2018. Charcot-Marie-Tooth disease type 4C in Norway: Clinical characteristics, mutation spectrum and minimum prevalence. Neuromuscular Disorders. 639-645.
  • 2018. Antibody response to seasonal influenza vaccination in patients with multiple sclerosis receiving immunomodulatory therapy. European Journal of Neurology. 527-534.
  • 2018. Antibodies to multiple receptors are associated with neuropsychiatric symptoms and mortality in Alzheimer's disease: A longitudinal study. Journal of Alzheimer's Disease. 761-774.
  • 2017. Selective intrathecal enrichment of G1m1-positive B cells in multiple sclerosis. Annals of clinical and translational neurology. 756-761.
  • 2017. Neurofilament light chain predicts disease activity in relapsing-remitting MS. Neurology: Neuroimmunology and neuroinflammation. 1-8.
  • 2017. Multippel sklerose - en mitokondriemediert sykdom? Tidsskrift for Den norske legeforening. 274-287.
  • 2017. Cerebellar degeneration-related proteins 2 and 2-like are present in ovarian cancer in patients with and without Yo antibodies. Cancer Immunology and Immunotherapy. 1463-1471.
  • 2017. Assays for Infliximab Drug Levels and Antibodies: A Matter of Scales and Categories. Scandinavian Journal of Immunology. 165-170.
  • 2017. Antibodies to signaling molecules and receptors in Alzheimer's disease are associated with psychomotor slowing, depression, and poor visuospatial function. Journal of Alzheimer's Disease. 929-939.
  • 2016. Prostate cancer, Hu antibodies and paraneoplastic neurological syndromes. Journal of Neurology. 1001-1007.
  • 2016. Multicentre comparison of a diagnostic assay: Aquaporin-4 antibodies in neuromyelitis optica. Journal of Neurology, Neurosurgery and Psychiatry. 1005-1015.
  • 2016. Increased levels of cell-free mitochondrial DNA in the cerebrospinal fluid of patients with multiple sclerosis. Mitochondrion (Amsterdam. Print). 32-35.
  • 2016. A case of relapsing-remitting facial palsy and ipsilateral brachial plexopathy caused by HSV-1. Journal of Clinical Virology. 62-65.
  • 2015. Paraneoplastic syndrome-associated neuronal antibodies in adult ADHD. Journal of Neuroimmunology. 87-91.
  • 2015. Paraneoplastic neurological syndromes in lung cancer patients with or without onconeural antibodies. Journal of the Neurological Sciences. 41-45.
  • 2015. Fingolimod does not enhance cerebellar remyelination in the cuprizone model. Journal of Neuroimmunology. 180-186.
  • 2015. Biomarkers related to carotid intima-media thickness and plaques in long-term survivors of ischemic stroke. Translational Stroke Research. 276-283.
  • 2015. Autoantibodies toward the angiotensin 2 type 1 receptor: a novel autoantibody in Alzheimer's Disease. Journal of Alzheimer's Disease. 523-529.
  • 2014. Paraneoplastic Hu and CRMP5 antibodies are present in smokers without cancer or neurological disease. Respirology (Carlton South. Print). 730-734.
  • 2014. Paraneoplastic CDR2 and CDR2L antibodies affect Purkinje cell calcium homeostasis. Acta Neuropathologica. 835-852.
  • 2014. Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: An explorative study. Multiple Sclerosis. 1074-1080.
  • 2014. Deficient phosphorylation of stat-1 in leukocytes identifies neutralizing antibodies in multiple sclerosis patients treated with interferon-beta. PLOS ONE.
  • 2013. The Norwegian stroke in the young study (NOR-SYS): rationale and design. BMC Neurology. 12 pages.
  • 2013. Progressive striatal necrosis associated with anti-NMDA receptor antibodies. BMC Neurology. 4 pages.
  • 2013. Neurological manifestations related to level of voltage-gated potassium channel antibodies. Journal of Neurology, Neurosurgery and Psychiatry. 941-943.
  • 2013. Ischaemic stroke at a young age is a serious event final results of a population-based long-term follow-up in Western Norway. European Journal of Neurology. 818-823.
  • 2013. Discovery and initial verification of differentially abundant proteins between multiple sclerosis patients and controls using iTRAQ and SID-SRM. Journal of Proteomics. 312-325.
  • 2013. Chronic inflammatory demyelinating polyneuropathy (CIDP). Acta Neurologica Scandinavica. 48-51.
  • 2013. CDR2L antibodies: a new player in paraneoplastic cerebellar degeneration. PLOS ONE.
  • 2013. Avidity of onconeural antibodies is of clinical relevance. Cancer Immunology and Immunotherapy. 1393-1396.
  • 2012. Immunogenic effects of recombinant interferon-beta therapy disrupt the JAK/STAT pathway in primary immune cells from patients with multiple sclerosis. Multiple Sclerosis. 1116-1124.
  • 2012. Identification of continuous epitopes of HuD antibodies related to paraneoplastic diseases/small cell lung cancer. Journal of Neuroimmunology. 25-33.
  • 2012. Fcγ receptors in Norwegian multiple sclerosis patients and healthy controls. Acta Neurologica Scandinavica, Supplementum. 84-89.
  • 2012. Cerebrospinal fluid proteome comparison between multiple sclerosis patients and controls. Acta Neurologica Scandinavica. 90-96.
  • 2011. Screening for tumours in paraneoplastic syndromes: report of an EFNS Task Force. European Journal of Neurology. 19-E3.
  • 2011. Onconeural antibodies: Improved detection and clinical correlations. Journal of Neuroimmunology. 166-170.
  • 2011. Onconeural antibodies in patients with neurological symptoms: detection and clinical significance. Acta Neurologica Scandinavica. 83-88.
  • 2011. Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab. Multiple Sclerosis. 1074-1078.
  • 2011. CDR2 antigen and Yo antibodies. Cancer Immunology and Immunotherapy. 283-289.
  • 2010. Neurofilament ELISA validation. JIM - Journal of Immunological Methods. 23-31.
  • 2010. Mutations in ABHD12 Cause the Neurodegenerative Disease PHARC: An Inborn Error of Endocannabinoid Metabolism. American Journal of Human Genetics. 410-417.
  • 2010. Antibody to CCDC104 is associated with a paraneoplastic antibody to CDR2 (anti-Yo). Cancer Immunology and Immunotherapy. 231-237.
  • 2010. A multivariate approach to reveal biomarker signatures for disease classification: application to mass spectral profiles of cerebrospinal fluid from patients with multiple sclerosis. Journal of Proteome Research. 3608-3620.
  • 2009. Onconeural antibodies in sera from patients with various types of tumours. Cancer Immunology and Immunotherapy. 1795-1800.
  • 2009. Fatigue, pain and muscle weakness are frequent after Guillain-Barré syndrome and poliomyelitis. Journal of Neurology. 349-354.
  • 2009. CRMP5 antibodies found in a patient with limbic encephalitis and myasthenia gravis. Journal of Neurology, Neurosurgery and Psychiatry. 241-242.
  • 2009. Antibodies against interferon-beta in multiple sclerosis. Journal of Neuroimmunology. 148-150.
  • 2008. Ultrasound, atherosclerosis and stroke at a young age: a cross-sectional long-term follow-up in western Norway. European Journal of Neurology. 512-519.
  • 2008. Proteasome antibodies in patients with cancer or multiple sclerosis. Scandinavian Journal of Immunology. 400-403.
  • 2008. Microarray analysis reveals down-regulation of the tumour suppressor gene WWOX and up-regulation of the oncogene TYMS in intracranial sporadic meningiomas. Journal of Neuro-Oncology. 251-259.
  • 2008. CRMP5 antibodies in patients with small-cell lung cancer or thymoma. Cancer Immunology and Immunotherapy. 227-232.
  • 2007. Pretreatment of mass spectral profiles: Application to proteomic data. Analytical Chemistry. 7014-7026.
  • 2007. Pre-analytical influence on the low molecular weight cerebrospinal fluid proteome. PROTEOMICS - Clinical Applications. 699-711.
  • 2007. Long-term mortality among young ischemic stroke patients in western Norway. Acta Neurologica Scandinavica. 150-156.
  • 2007. Isoelectric focusing is superior to immunofixation electrophoresis in diagnosing CNS inflammation. Acta Neurologica Scandinavica. 122-125.
  • 2007. Hu and Yo antibodies have heterogeneous avidity. Journal of Neuroimmunology. 162-167.
  • 2007. Fc gamma receptor polymorphisms are not associated with autoimmune Addison's disease. Scandinavian Journal of Immunology. 555-558.
  • 2007. Arterial events after ischemic stroke at a young age: A cross-sectional long-term follow-up of patients and controls in western Norway. Cerebrovascular Diseases. 277-282.
  • 2007. Antibodies to CRMP3-4 associated with limbic encephalitis and thymoma. Clinical and Experimental Immunology. 16-22.
  • 2006. cDNA expression library screening for identification of novel onconeural antigens. Acta Neurologica Scandinavica. 73-74.
  • 2006. Yo antibodies in ovarian and breast cancer patients detected by a sensitive immunoprecipitation technique. Clinical and Experimental Immunology. 53-58.
  • 2006. Ri antibodies in patients with breast, ovarian or small cell lung cancer determined by a sensitive immunoprecipitation technique. Cancer Immunology and Immunotherapy. 1280-1284.
  • 2006. Multiplexed phosphoprotein analysis in immune cells. Acta Neurologica Scandinavica. 58-60.
  • 2006. Management of paraneoplastic neurological syndromes: report of an EFNS Task Force. European Journal of Neurology. 682-690.
  • 2006. Fc gamma R and multiple sclerosis: an overview. Acta Neurologica Scandinavica. 61-63.
  • 2006. Detection of autoantibodies to the BTB-kelch protein KLHL7 in cancer sera. Scandinavian Journal of Immunology. 325-335.
  • 2006. Bergen International symposium in neuroimmunology 2006. Introduction. Acta Neurologica Scandinavica, Supplementum. v-vi.
  • 2006. Autopsy findings in the nervous system and ovarian tumour of two patients with paraneoplastic cerebellar degeneration. Acta Neurologica Scandinavica. 69-70.
  • 2006. An immunprecipitation assay for the detection of onconeural antibodies. Acta Neurologica Scandinavica. 71-72.
  • 2005. Proteasome antibodies in paraneoplastic cerebellar degeneration. Journal of Neuroimmunology. 172-178.
  • 2005. Neurological symptoms as the first sign of cancer: Paraneoplastic encephalomyelitis and sensory neuronopathy. American Journal of Oncology Review. 31-34.
  • 2005. High dose methylprednisolone induces FcgammaR1 on granulocytes in MS-patients. Journal of Neuroimmunology. 138-142.
  • 2005. Fc gamma receptor IIIA polymorphism as a risk-factor for coronary artery disease. Atherosclerosis. 277-282.
  • 2005. Ethnic variations of IL-10 polymorphisms in a Sami and Norwegian population. Scandinavian Journal of Immunology. 71-74.
  • 2005. Ethnic variation of Fc gamma receptor polymorphism in Sami and Norwegian populations. Immunology. 416-421.
  • 2004. The effects of interferon-alpha2a on concentrations of immunoglobulins, complement and lymphocytes in patients with multiple sclerosis. Scandinavian Journal of Immunology. 103-108.
  • 2004. Systemic complement activation following human acute ischaemic stroke. Clinical and Experimental Immunology. 117-122.
  • 2004. Recommended diagnostic criteria for paraneoplastic neurological syndromes. Journal of Neurology, Neurosurgery and Psychiatry. 1135-1140.
  • 2004. Pyridoxal phosphatase is a novel cancer autoantigen in the central nervous system. British Journal of Cancer. 1508-1514.
  • 2004. Paraneoplastic antibodies detected by isoelectric focusing of cerebrospin fluid and serum. Journal of Neuroimmunology. 150-154.
  • 2004. Paraneoplastic antibodies against HuD detected by a sensitive radiobinding assay. Journal of Neurology. 197-203.
  • 2004. Hu and voltage-gated calcium channel (VGCC) antibodies related to the prognosis of small-cell lung cancer. Journal of Clinical Oncology. 795-800.
  • 2004. Heterogeneous expression of CD59 on human Purkinje cells. Neuroscience Letters. 21-25.
  • 2002. Molecular genetic diagnosis of Charcot-Marie-Tooth disease and hereditary neuropathy with liability to pressure palsies. Tidsskrift for Den norske legeforening. 382-385.
  • 2001. Recombination breakpoints in the Charcot-Marie-Tooth 1A repeat sequence in Norwegian families. Acta Neurologica Scandinavica. 97-100.
  • 2001. Molecular genetic analysis of Charcot-Marie-Tooth 1A duplication in Norwegian patients by quantitative photostimulated luminiscence imaging. Journal of the Neurological Sciences. 21-26.
  • 2001. Hereditary neuropathy with pressure palsies. Tidsskrift for Den norske legeforening. 426-428.
  • 2001. Disability and prognosis in multiple sclerosis: demographic and clinical variables important for the ability to walk and awarding of disability pension. Multiple Sclerosis. 59-65.
  • 2001. Disability and prognosis in multiple sclerosis: demographic and clinical variables important for the ability to walk and awarding of disability pension. Multiple Sclerosis. 59-65.
  • 2000. Real-time quantitative polymerase chain reaction. A new method that detects both the peripheral myelin protein 22 duplication in Charcot-Marie-Tooth type 1A disease and the peripheral myelin protein 22 deletion in hereditary neuropathy with liability to pressure palsies. Human Genetics. 494-498.
  • 2000. Polynevropati er et tidlig funn ved primært systemisk amyloidose. Tidsskrift for Den norske legeforening. 1291-1293.
  • 2000. Polynevropati er et tidlig funn ved primært systemisk amyloidose. Tidsskrift for Den norske legeforening. 1291-1293.
  • 2000. Oligoclonal bands in cerebrospinal fluid: a comparative study of isoelectric focusing, agarose gel electrophoresis and IgG index. Acta Neurologica Scandinavica. 322-325.
  • 2000. Oligoclonal bands in cerebrospinal fluid: a comparative study of isoelectric focusing, agarose gel electrophoresis and IgG index. Acta Neurologica Scandinavica. 322-325.
  • 2000. Nevrologisk sykdom assosiert med cøliaki. Tidsskrift for Den norske legeforening. 439-442.
  • 2000. Nevrologisk sykdom assosiert med cøliaki. Tidsskrift for Den norske legeforening. 439-442.
  • 2000. Neutralizing antibodies to interferon (IFN)alfa-2a and IFN beta-1a or IFN beta-1b in MS are not cross-active. Neurology. 1569-1571.
  • 2000. Neutralizing antibodies to interferon (IFN)alfa-2a and IFN beta-1a or IFN beta-1b in MS are not cross-active. Neurology. 1569-1571.
  • 2000. Interferon-alfa2a effects on complement and regulation in MS patients. Acta Neurologica Scandinavica. 30-35.
  • 2000. Inflammatory neuropathies: update. Current Opinion in Neurology. 305-309.
  • 2000. Inflammatory neuropathies: update. Current Opinion in Neurology. 305-309.
  • 2000. Inerteron-alfa2a effects on complement and regulation in MS patients. Acta Neurologica Scandinavica. 30-35.
  • 2000. Inerteron-alfa2a effects on complement and regulation in MS patients. Acta Neurologica Scandinavica. 30-35.
  • 2000. IgG Fc-receptor polymorphisms in Guillain-Barre syndrome. Neurology. 705-707.
  • 2000. IgG Fc-receptor polymorphisms in Guillain-Barre syndrome. Neurology. 705-707.
  • 2000. EFNS Task Force Report: a questionnaire-based survey on the service provision and quality assurance for determination of diagnostic autoantibody tests in European neuroimmunology centres. European Journal of Neurology. 625-628.
  • 2000. Complement activation by titin and ryanoidine receptor autoantibodies in myasthenia gravis. Journal of Neuroimmunology. 169-176.
  • 2000. Complement activation by titin and ryanodine receptor autoantibodies in myasthenia gravis. Journal of Neuroimmunology. 169-176.
  • 1999. The expression of CD59 in experimental allergic neuritis. Journal of Neurological Sciences. 154-159.
  • 1999. Interferon-alpha 2a reduces MRI disease activity in relapsing-remittingmultiple sclerosis. Neurology. 1049-1056.
  • 1999. Immunoglobulin G, Fc-receptor IIA and IIB plymorphisms related to disease severity in rheumatoid arthritis. Arthritis and Rheumatism. 1045-Abstract.
  • 1999. Immunoglobulin G Fc-receptor (Fc gamma R) IIA and IIIB polymorphisms related to disability in MS. Neurology. 1771-1776.
  • 1998. POEMS-syndromet - en sjelden multiorgansykdom. Tidsskrift for Den norske legeforening. 3274-3277.
  • 1998. FcgRIIA and RIIIB polymorphisms in myasthenia gravis. Journal of Neuroimmunology. 173-176.
  • 1998. Cerebral amyloid angiopati (CAA). Tidsskrift for Den norske legeforening. 3123-3126.
  • 1998. Cerebral amyloid angiopati. Tidsskrift for Den norske legeforening. 3123-3126.
  • 1998. Altered antibody pattern to Epstein-Barr virus but not to other herpesviruses in multiple sclerosis: a population based case-control study from western Norway. Journal of Neurology, Neurosurgery and Psychiatry. 539-542.
  • 1998. Altered antibody pattern to Epstein-Barr virus but not to other herpesviruses in multiple sclerosis: a population based case-control study from western Norway. Journal of Neurology, Neurosurgery and Psychiatry. 539-542.
  • 1998. Altered antibody pattern to Epstein-Barr virus but not to other herpes viruses in multiple sclerosis: a population based case-control study from western Norway. Journal of Neurology, Neurosurgery and Psychiatry. 539-542.
  • 1997. The long-term prognosis of Guillain-Barré syndrome.Evaluation of prognostic factors including plasma exchange. Acta Neurologica Scandinavica. 298-302.
  • 1997. Paraneoplastisk cerebellar degenerasjon. En kasustikk. Tidsskrift for Den norske legeforening. 2947-2948.
  • 1996. Soluble complement receptor type 1 in serum and cerebrospinal fluid of patients with Guillain-Barre syndrome and multiple sclerosis. Journal of Neuroimmunology. 17-20.
  • 1996. Soluble complement receptor type 1 in serum and cerebrospinal fluid of patients with Guillain-Barr#/e syndrome and multiple sclerosis. Journal of Neuroimmunology. 17-20.
  • 1996. Guillain-Barré syndrome in northern Tanzania: a comparison of epidemical and clinical findings with western Norway. Acta Neurologica Scandinavica. 43-49.
  • 1996. Guillain-Barré syndrom; tema med variasjoner. Tidsskrift for Den norske legeforening. 242-245.
  • 1995. The influence of tumour necrosis factor-_a, interleukin-1_b and interferon-_g on the expression and function of the complement regulatory protein CD59 on the human colonic adenocarcinoma cell line HT29. Scandinavian Journal of Immunology. 350-356.
  • 1995. The influence of tumour necrosis factor-_a, interleukin-1_b and interferon-_g on the expression and function of the complement regulatory protein CD59 on the human colonic adenocarcinoma cell line HT29. Scandinavian Journal of Immunology. 350-356.
  • 1995. Spesielle interkraniale infeksjoner. Tidsskrift for Den norske legeforening. 1508-1511.
  • 1994. Varicella zoster-infeksjoner og neurologiske komplikasjoner. Tidsskrift for Den norske legeforening. 2484-2486.
  • 1994. Varicella zoster-infeksjoner og neurologiske komplikasjoner. Tidsskrift for Den norske legeforening. 2484-2486.
  • 1994. Varicella zoster-infeksjoner of neurologiske komplikasjoner. Tidsskrift for Den norske legeforening. 2484-2486.
  • 1994. The expression of CD59 in normal human nervous tissue. Immunology. 542-547.
  • 1994. The expression of CD59 in normal human nervous tissue. Immunology. 542-547.
  • 1994. The expression of CD59 in normal human nervous tissue. Immunology. 542-547.
  • 1994. Receptors for gammaglobulin in the central and peripheral nervous system. Journal of Neurology, Neurosurgery and Psychiatry. 9-10.
  • 1994. Receptors for gammablobulin in the central and preipheral nervous system. Journal of Neurology, Neurosurgery and Psychiatry. 9-10.
  • 1994. Reactive microglia in multiple sclerosis lesions have an increased expression of receptors for the Fc part of IgG. Journal of Neurological Sciences. 125-131.
  • 1994. Reactive microglia in multiple sclerosis lesions have an increased expression of receptors for the Fc part of IgG. Journal of the Neurological Sciences. 125-131.
  • 1994. Reactive microglia in multiple sclerosis lesions have an increased expression of receptors for the Fc part of IgG. Journal of the Neurological Sciences. 125-131.
  • 1994. Felles vaktordning for det "medisinske fagfelt", Haukeland sykehus. Axonet. 6.
  • 1994. Fc receptor for IgG (FcR) on rat microglia. Journal of Neuroimmunology. 19-24.
  • 1994. Fc receptor for IgG (FcR) on rat microglia. Journal of Neuroimmunology. 19-24.
  • 1994. Expression and function of CD59 on colonic adenocarcinoma cells. European Journal of Immunology. 1597-1603.
  • 1994. Expression and function of CD59 on colonic adenocarcinoma cells. European Journal of Immunology. 1597-1603.
  • 1994. A dot-immunobinding for the demonstration of soluble Fc_g receptors. JIM - Journal of Immunological Methods. S. 15-19.
  • 1994. A dot-immunobinding assay for the demonstration of soluble Fc_g-receptors. JIM - Journal of Immunological Methods. 15-19.
  • 1993. Soluble CD59 in pregnancy and infancy. Immunology Letters. 233-234.
  • 1993. Fc receptor for IgG (FcR) on rat microglia. Journal of Neuroimmunology. 1-6.
  • 1993. CR1 activity on erythrocytes and renal glomeruli in patients with renal disorders. Nephrology, Dialysis and Transplantation. 1211-1214.
  • 1993. CR1 activity on erythrocytes and renal glomeruli in patients with renal disorders. Dialysis & Transplantation. 1211-1214.
  • 1993. CR1 activity on erythrocytes and renal glomeruli in patients with renal disorders. Nephrology, Dialysis and Transplantation. 1211-1211.
  • 1992. Peripheral nervous system (PNS) expression of mRNAs encoding myelin proteins and FC RIII during experimental allergic neuritis. Journal of Neuroimmunology. 43-50.
  • 1992. Expression of Genes Encoding Receptors for IgG (FcRIII) and for C3b/Cb4 (Crry) in Rat Sciatic Nerve During Development and Wallerian Degeneration. Journal of Neuroscience Research. 654-661.
  • 1991. Multippel sklerose - en immunologisk sykdom. Tidsskrift for Den norske legeforening. 944-947.
  • 1991. IgG Fc receptor heterogeneity in human peripheral nerves. Acta Neurologica Scandinavica. 177-180.
  • 1991. IgG Fc receptor heterogeneity in human peripheral nerves. Acta Neurologica Scandinavica. 177-180.
  • 1991. Antibodies in sera from patients with inflammatory demyelinating polyradiculoneuropathy react with ganglioside LM1 and sulphatide of peripheral nerve myelin. Journal of Neurology. 75-79.
  • 1990. Receptors for immunoglobulines demonstrated on human peripheral nerve fibres by electron microscopy. Neurosci Letters. 167-170.
  • 1990. Peripheral nerve CR1 limit complement-mediated haemolysis. Journal of Neuroimmunology. 95-98.
  • 1990. Mollarets meningitt. Tidsskrift for Den norske legeforening. 3346-3347.
Academic lecture
  • 2007. Target projection and proper data pre-treatment for the analysis of proteomic profiles.
  • 2007. Preteatment of Mass Spectral Profiles: Application to proteomic data.
  • 2007. Analysis of Proteomic Profiles.
  • 1995. Lomg-term prognosis in a incidence cohort of 219 Multiple Sclerosis patients from Hordaland county, Western Norway.
Popular scientific article
  • 1998. Evaluering av undervisning i nevrologi. UPED-skrift. 133-135.
  • 1997. Genetisk kartlegging av multippel sklerose. MS-bladet. 9-10.
  • 1991. Rapport fra studieopphold i USA. MS-bladet. 5-9.
Feature article
  • 1993. Soluble CD59 in pregnancy and infancy. Immunology Letters. 233-234.
Abstract
  • 2012. Single cell pStat1 activation, a promising biomarker to evaluate neutralizing antibody effects in interferon-beta treated multiple sclerosis patients. Journal of Neuroimmunology. 18-19.
  • 2012. Paraneoplastic neurological manifestations in patients with lung cancer without onconeural antibodies. Journal of Neuroimmunology. 133-133.
  • 2012. Hu antibodies are present in smokers with chronic obstructive pulmonary disease without cancer or neurological disease. Journal of Neuroimmunology. 21-22.
  • 2012. Characterization of Yo antibodies. Journal of Neuroimmunology. 131-132.
  • 2010. Update of the original pedigree of Hereditary Diffuse Leukoencephalopathy with Spheroids (HDLS). Insights into an underdiagnosed disease entity. European Journal of Neurology. 110-110.
  • 2010. Paraneoplastic Yo antibodies are not related to the presence of cerebellar degeneration-associated CDR2 antigen in ovarian cancer. Journal of Neuroimmunology. 191-191.
  • 2010. Genetic characterisation of PHARC - a novel syndrome resembling Refsum's disease. Neuromuscular Disorders. 680-680.
  • 2008. Interferon-beta signal transduction, multiple sclerosis and auto-antibodies. Journal of Neuroimmunology. 134-135.
  • 2008. Early diagnosis and biomarker discovery from mass spectral profiles: application to multiple sclerosis. Multiple Sclerosis. S285-S285.
  • 2008. Biomarker discovery from mass spectral profiles: A combined proteomics and multivariate analysis. European Journal of Pharmaceutical Sciences. S27-S27.
  • 2008. Anti-ccdc104 is a potentially new onconeural antibody. Journal of Neuroimmunology. 190-191.
  • 2007. Mortality and vascular morbitity after ischemic stroke at a young age. Cerebrovascular Diseases.
  • 2004. CRMP3 antibodies associated with limbic encephalitis and thymoma. Journal of Neuroimmunology.
Academic literature review
  • 2019. Neurofilament light chain as a biomarker in multiple sclerosis. 1-6.
  • 2013. Neuromyelitis optica. 2057-2061.
  • 2012. Treatment for paraneoplastic neuropathies. 22 pages.
  • 2010. Intravenøs IgG-behandling av nevromuskulære sykdommer :. 1717-1720.
  • 2009. Paraneoplastiske nevrologiske syndromer. 524-528.
  • 2009. Autoimmune limbic encephalitis. 63-67.
  • 2007. Paraneoplastic neurological syndromes and onconeural antibodies: Clinical and immunological aspects. 143-185.
  • 2006. Proteomic-based biomarker discovery with emphasis on cerebrospinal fluid and multiple sclerosis. 147-158.
Article in business/trade/industry journal
  • 2014. Satsingen på medisinsk forskning kan bli svekket. Dagens medisin.

More information in national current research information system (CRIStin)

Fields of competence